Keyword: Entresto

Thanks to Novartis' MedCo buyout pact, PCSK9 competition is about to get more intense. But can it really make its heart prospect work?

After Merck and Bayer's vericiguat scored in a heart failure trial, you'd expect potential rivals to brace themselves. Not so for Novartis' Entresto.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Zolgensma hauled in $160 million in its first full quarter on the market, more than 60% above the Street's expectations.

AstraZeneca's Farxiga has new CV data that could help the entire SGLT2 class—and even pressure heart medicines outside the class, too. 

With a trial setback for its $5 billion CV hopeful in its way, Novartis is looking at the bright side—Entresto flopped, but it was a “narrow miss.”

Novartis envisioned $5 billion in peak sales for its cardiovascular drug Entresto, but, after a major trial flop, that goal appears out of reach.

Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”

A handful of branded drug ads are using popular ‘70s light rock songs, both to aid recall and to reach older audiences with music from their youth.

Cosentyx and Entresto delivered strong growth again, but Novartis CEO Vas Narasimhan took pains to explain a death case in a Zolgensma trial.